About Contact Us Careers
Sign In

Cell Reprogramming Market - Top Companies and Manufacturers

  • Report ID: 5835
  • Published Date: Apr 30, 2024
  • Report Format: PDF, PPT

Companies Dominating the Cell Reprogramming Landscape

    • Bio-Techne
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Human Longevity Inc.
    • Lineage Cell Therapeutics
    • Mesoblast
    • Advanced Cell Technology Inc
    • Lonza
    • STEMCELL Technologies Inc.
    • Astellas Pharma Inc.
    • ALSTEM
    • Mogrify Limited
Browse Key Market Insights with Data Illustration:

In the News

  • Mogrify Limited - Mogrify Limited and Astellas Pharma Inc. announced a collaboration to conduct research on in vivo regenerative medicines approaches to address sensorineural hearing loss. The collaboration will seek to recognize novel combinations of factors that are included in cell differentiation to generate new cochlear hair cells.
  • Mesoblast - Mesoblast announced a partnership with Blood and Marrow Transplant Clinical Trials Network (BMT CTN) for a clinical investigation and carry out the study that will assess Ryoncil in individuals 12 years of age and older who have not responded to first-line therapies such as corticosteroids or ruxolitinib.

Author Credits:  Radhika Pawar


  • Report ID: 5835
  • Published Date: Apr 30, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing popularity of personalized medicine, the surging prevalence of neurodegenerative diseases, and the increasing geriatric population are the major factors driving the growth of the market.

The market size of cell reprogramming is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market are Bio-Techne, Human Longevity Inc., Lineage Cell Therapeutics, Mesoblast, Advanced Cell Technology Inc, Lonza, STEMCELL Technologies Inc., Astellas Pharma Inc., ALSTEM, Mogrify Limited, and others.

The induced pluripotent stem cells segment is anticipated to garner the largest market size of 45% by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share of 44% by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample